Overview of BRAF and V600E Mutation
- Gene: BRAF (v-raf murine sarcoma viral oncogene homolog B1)
- Protein Function: Serine/threonine kinase in the RAS–RAF–MEK–ERK (MAPK) signaling pathway → regulates cell proliferation, survival, and differentiation.
- Mutation: V600E
- Substitution of valine (V) with glutamic acid (E) at codon 600
- Causes constitutive activation of BRAF → uncontrolled MAPK signaling → oncogenesis
- Type: Gain-of-function mutation
2. Tumors Associated with BRAF V600E
| Tumor Type | Approximate Frequency | Notes |
|---|---|---|
| Melanoma | 40–60% | Most common actionable mutation in melanoma |
| Colorectal cancer | 8–10% | Poor prognosis; usually right-sided tumors |
| Non-small cell lung cancer (NSCLC) | 1–2% | Mainly adenocarcinoma |
| Papillary thyroid carcinoma | 40–45% | Associated with aggressive phenotype |
| Hairy cell leukemia | >90% | Nearly diagnostic in this rare leukemia |
| Other | Low frequency | Ovarian, biliary, gliomas |
3. Clinical Implications
- Prognostic:
- Often poor prognosis in colorectal cancer and melanoma if untreated
- Predictive:
- Predicts response to BRAF-targeted therapies
- Can influence combination therapy decisions (e.g., BRAF + MEK inhibitors)
4. Targeted Therapies for BRAF V600E
| Drug | Class | Indication | Notes |
|---|---|---|---|
| Vemurafenib | BRAF inhibitor | Metastatic melanoma, NSCLC | Often combined with MEK inhibitor to prevent resistance |
| Dabrafenib | BRAF inhibitor | Melanoma, NSCLC, thyroid | Often combined with trametinib (MEK inhibitor) |
| Encorafenib | BRAF inhibitor | Metastatic colorectal cancer | Used with cetuximab (anti-EGFR) for BRAF V600E CRC |
| Trametinib | MEK inhibitor | Combined with BRAF inhibitors | Reduces resistance and skin toxicity |
Key Concept:
-
BRAF inhibitor monotherapy can lead to paradoxical MAPK activation in non-BRAF mutant cells → combination with MEK inhibitor is standard.
5. Resistance Mechanisms
- Reactivation of MAPK pathway via:
- Activation of PI3K–AKT pathway as bypass
6. Pharmacology / Monitoring Notes
- Adverse Effects:
- Rash, photosensitivity, arthralgia, fatigue, fever
- BRAF inhibitor–related cutaneous squamous cell carcinoma (less common with combo therapy)
- Monitoring:
- CBC, liver function, skin exams, ECG if combo therapy
Clinical Summary:
- BRAF V600E is an actionable oncogenic driver in multiple cancers.
- Testing for V600E mutation is essential for targeted therapy selection.
- Combination therapy (BRAF + MEK inhibitors) is standard in melanoma and colorectal cancer to improve efficacy and reduce resistance.